One-Time bladder treatment after kidney surgery may stop cancer comeback
NCT ID NCT07591805
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of the drug disitamab vedotin, given directly into the bladder right after kidney removal surgery, can prevent bladder cancer from coming back. It involves 49 adults with HER2-positive upper tract cancer who are at risk for recurrence. The main goal is to see how many people stay cancer-free in the bladder for at least 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists create new tools to fight rare urinary tract cancer
- Could chemo before surgery beat cancer better?
- New cancer gel shows promise for rare urinary tract tumors
- New drug combo aims to spare kidneys in High-Risk urinary tract cancer
- New combo aims to stop rare Cancer's return after surgery
- Major european study tests if Kidney-Saving surgery is safe for rare cancer